Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Jeffrey R. Infante, Philippe L. Bedard, Geoffrey Shapiro, Todd Michael Bauer, Amy Prawira, Oscar Laskin, Marla Weetall, John Baird, Art Branstrom, Edward O'Mara, Robert J. Spiegel; Sarah Cannon |
Title | Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein. |
Journal | J Clin Oncol |
Vol | |
Issue | |
Date | |
URL | http://abstracts.asco.org/199/AbstView_199_189820.html |
Abstract Text | J Clin Oncol 35, 2017 (suppl; abstr 2574) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | PTC596 | Phase I | Actionable | In a Phase I trial, PTC596 demonstrated safety and preliminary efficacy, resulted in stable disease in 16% (5/31) of patients with advanced solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2574)). | detail... |